At this year’s European Society for Medical Oncology, excitement topped 2022 levels on NSCLC and breast cancer innovation.
The company’s blockbuster cancer asset Keytruda brought in more than $6.3 billion in the third quarter, a 17% increase from the same period last year, while bolstering its antibody-drug conjugate portfolio.
The companies presented data from two pivotal studies of Dato-DXd, focusing on safety concerns and survival data for the investigational antibody-drug conjugate candidate in lung and breast cancer.
MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink’s ADC assets, and BioNTech will provide MediLink with an upfront payment totaling of $70 million and additional development, regulatory and commercial milestone payments potentially totaling over $1 billion.
AstraZeneca said on its experimental precision drug had slowed the progression of a common type of breast cancer in a late-stage trial, a boost for the company after its shares fell in July on results from a separate trial of the same drug for lung cancer.
Let’s think of this Barbie phenomenon as a catalyst to put women’s health and well-being at the forefront. How can we, as pharma marketers, keep the momentum going?
Today the company announced that its breast cancer therapy in combination with Roche’s Kadcyla helped extend the time patients lived without their disease progressing in a late-stage trial.
The study showed that the therapy was able to help clear all signs of tumor in patients compared to neo-adjuvant placebo plus chemotherapy.
Monday, February 13, 2023, was a typical day for me as a healthcare marketer and busy mom of two, aside from having my yearly 3D mammogram. Fast forward a few days to Thursday the 16th, at 3:56 PM, which kicked off a scary period in my life. The “C word.”
Novartis’ breast cancer drug Kisqali cut the risk of recurrence by a little more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and challenging strong rival Eli Lilly.